FRAXA Clinical Trial Grant
FRAXA Clinical Trial Grant supports scientists studying people with Fragile X syndrome, prioritizing trials of disease-modifying treatments to advance practical therapies and ultimately a cure.
Browse similar grants
Funder: FRAXA Research Foundation
Due Dates: Rolling (Clinical Trial applications; no deadline)
Funding Amounts: No requested amount limit; flexible funding structure and duration, with yearly renewal for multiyear grants
Summary: Supports clinical research involving people with Fragile X syndrome, prioritizing disease-modifying treatment trials.
Key Information: Institutions must waive indirect costs; a Letter of Intent is required before applying.
Description
FRAXA Research Foundation supports clinical research involving people with Fragile X syndrome to advance specific treatments and ultimately a cure. The foundation accepts proposals from scientists worldwide and aims to bring practical therapies into medical practice as quickly as possible. It prioritizes projects with clear practical applications and prompt sharing of results.
The highest priority is clinical trials of potentially disease-modifying agents already validated in Fragile X animal models, particularly through earlier FRAXA-funded research. Biomarker studies in Fragile X patients and trials of symptomatic therapies are also considered, but receive lower priority. FRAXA emphasizes therapeutics grounded in an understanding of Fragile X disease mechanisms. Clinical trials are now a high priority in its strategy to address bottlenecks in treatment development.
